Recent Initiatives Provide Approximately $8 Million of Non-Dilutive, Incremental Liquidity through Various Amendments with Lenders Recent Initiatives Provide Approximately $8 Million of Non-Dilutive, Incremental Liquidity through Various Amendments with Lenders
More:
Lifecore Biomedical Completes Incremental Liquidity Initiatives
MISSISSAUGA, Ontario, May 16, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on June 15, 2024, to shareholders of record at the close of business on May 31, 2024. This second quarter 2024 dividend compares with the first quarter 2024 dividend of $0.045 per common share. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors.
Read the original here:
BioSyent Declares Second Quarter 2024 Dividend
MISSISSAUGA, Ontario, May 16, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q1) ended March 31, 2024. Key highlights include:
Continue reading here:
BioSyent Releases Financial Results for Q1 2024
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, as well as new and updated data related to novel investigational hematological malignancy therapies HMPL-306, HMPL-760 and tazemetostat, will be presented at the upcoming European Hematology Association (“EHA”) Hybrid Congress, taking place on June 13-16, 2024 in Madrid, Spain and online.
The rest is here:
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an underwritten offering of 86,486,486 shares of its common stock at a price of $1.85 per share. All of the shares to be sold in the offering are to be sold by Erasca. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $160 million. In addition, Erasca has granted the underwriters a 30-day option to purchase up to an additional 12,972,972 shares of common stock at the offering price. The offering is expected to close on May 21, 2024, subject to the satisfaction of customary closing conditions.
More here:
Erasca Announces Pricing of Underwritten Offering of Common Stock
Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors
See the rest here:
Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise
STOCKHOLM, Sweden, May 17, 2024 (GLOBE NEWSWIRE) -- QuTEM AB (formerly Vironova BioAnalytics AB), a leading provider of transmission electron microscopy (TEM) services, proudly announces the receipt of GMP (Good Manufacturing Practice) Certificates and Manufacturing Permits for Independent Quality Control Laboratories issued by the Swedish Medical Products Agency (Läkemedelsverket). QuTEM is thereby authorized to perform critical quality control analysis essential for the release of medicines to the market. The GMP Certificates and Manufacturing Permits cover medicinal and investigational medicinal products for both human and veterinary use.
See the original post here:
QuTEM Receives GMP Certificates and Manufacturing Permits for Transmission Electron Microscopy Laboratory from the Swedish Medical Products Agency
CARMEL, N.Y., May 15, 2024 /PRNewswire/ -- Dr. Douglas J. Fauser, a prominent sports medicine and total joint replacement specialist of the Somers Orthopaedic Surgery & Sports Medicine Group, along with Dr. Michael Baroody, a Board-Certified Plastic Surgeon, have achieved a groundbreaking milestone in orthopaedic medicine the first of its kind performed at the Orthopaedic & Spine Surgery Center (OSSC). On April 22, they successfully performed the first autologous live stem cell knee injection using cutting-edge technology. This revolutionary procedure, conducted under general anesthesia, involved the administration of purified concentrated live stem cells derived from the patient's own abdominal fat.
Dr. Fauser, who has dedicated over 30 years to delivering high-quality and cost-effective surgical solutions, is leading the way in non-operative treatments for osteoarthritis. The use of autologous stem cells represents a significant advancement in medical treatments, providing patients with an aggressive yet non-surgical option to manage the debilitating effects of osteoarthritis in knees.
"We are on the brink of a major shift in how we treat osteoarthritis," stated Dr. Fauser. "This first-of-its-kind procedure at OSSC utilizes autologous live stem cells, derived from the patient's own body, to potentially revolutionize the management of joint degeneration. Our goal is not just to alleviate symptoms but to target the underlying causes of osteoarthritis, offering patients a promising new pathway to recovery without surgery."
Fat tissue, which is known for its cushioning and supportive roles, contains a high concentration of reparative cells that may enhance the healing process. The innovative use of microfragmented adipose tissue, processed by the LIPOGEMS device, exemplifies the potential of fat to play a critical role in orthopaedic and arthroscopic surgeries.
The procedure underscores the advantages of using adipose tissue in orthopaedics, including its minimal invasiveness, abundance, and superior quality compared to other similar tissues. Research, supported by over 160 peer-reviewed publications, confirms the efficacy and safety of using microfragmented fat in various body areas including shoulders, knees, hips, and feet.
This pioneering treatment by Drs. Fauser and Baroody at OSSC not only paves the way for future advancements in orthopaedic medicine but also reinforces the center's commitment to providing innovative care that adheres to the highest standards of excellence. The Orthopedic & Specialty Surgery is a leading multi-specialty surgical facility, located at Somers Orthopaedic Surgery & Sports Medicine Group's Danbury location, providing outstanding surgical and patient care for a wide range of musculoskeletal conditions.
About Somers Orthopaedic Surgery & Sports Medicine Group
Founded in 1988, the group has been at the forefront of diagnosing and treating musculoskeletal conditions. It is staffed by board-certified physicians specializing in various orthopaedic disciplines. For more details, visit somersortho.com.
SOURCE Somers Orthopaedic Surgery & Sports Medicine Group
See the rest here:
Dr. Douglas Fauser of Somers Orthopaedic Surgery & Sports Medicine Group Conducts First Autologous Live Stem ... - PR Newswire
Regular insulin and a syringe from ampoules and vials of medicines
Stem cells are being used more and more widely in treatments across the spectrum of medicine, but a recent breakthrough from Shanghai promises the best may still be yet to come.
A senior who had suffered from type-2 diabetes for 25 years hasnt taken insulin for 33 months after he received a regenerative islet cell transplantation.
Diabetes, particularly type 2the form that can develop in ones life because of poor diet and lifestyle choicesis one of the most prevalent non-communicable diseases on Earth.
China in particular is one of the worlds diabetes hotspots, with 140 million people unable to make their own insulin, and so suffer from kidney problems, blindness, amputation, and cardiovascular problems.
But this new breakthrough, coming after 10 years of research and testing, may change this paradigm of sickness forever.
Yin Hao, a leading researcher on the team and director of Shanghai Changzheng Hospitals Organ Transplant Center, said they took the patients own peripheral blood mononuclear cells and used existing methods to reprogram them back into pluripotent stem cells for injection into the pancreas.
Our technology has matured and it has pushed boundaries in the field of regenerative medicine for the treatment of diabetes, Yin, told China Daily whose team conducted the research with scientists from the Center for Molecular Cell Science at the Chinese Academy of Sciences.
Existing transplant treatments for type-2 diabetes are hindered by a lack of donor cells, and the complexity of pancreatic islet cell isolation technology.
ALSO CHECK OUT: Worlds First Tooth Regrowth Medicine Moves Toward Clinical Trials in Japan
Pancreatic islet cells are the major insulin-producing cells in the body, and the patients were almost completely inhibited. He relied on multiple insulin injections daily in addition to a kidney transplant.
After receiving the manufactured stem cells in 2021, he was weened off of external insulin over 11 weeks, after which his disease seemed to be largely gone.
MORE GOOD NEWS FOR DIABETES SUFFERERS: Crazy Insulin Prices Now a Thing of the Past in U.S. After Government Initiates Monthly Cost of $35
Follow-up examinations showed that the patients pancreatic islet function was effectively restored, and his renal function was within normal range, Yin said. Such results suggested that the treatment can avoid the progression of diabetic complications.
The paper was published in Cell Discovery on April 30th, and future studies, the authors wrote, should explore the pharmacology of drugs that might provide off-the-shelf equivalents for islet transplantation.
SHARE This Miracle Of Modern Medicine With Someone You Know With Diabetes
Original post:
59-year-old Man Who Had Type 2 Diabetes for 25 Years is Cured by Stem Cells - Good News Network
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Hematopoietic Stem Cell Transplantation pipeline constitutes 20+ key companies continuously working towards developing 20+ Hematopoietic Stem Cell Transplantation treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Hematopoietic Stem Cell Transplantation Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hematopoietic Stem Cell Transplantation Market.
The Hematopoietic Stem Cell Transplantation Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Hematopoietic Stem Cell Transplantation Pipeline Report: https://www.delveinsight.com/sample-request/hematopoietic-stem-cell-transplantation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Companies across the globe are diligently working toward developing novel Hematopoietic Stem Cell Transplantation treatment therapies with a considerable amount of success over the years. Hematopoietic Stem Cell Transplantation companies working in the treatment market are Orchard Therapeutics, Lisata Therapeutics, Genenta science, Editas Medicine, Talaris Therapeutics, Inc., and others, are developing therapies for the Hematopoietic Stem Cell Transplantation treatment Emerging Hematopoietic Stem Cell Transplantation therapies in the different phases of clinical trials are- OTL-204, OTL-105, LSTA201, Temferon, EDIT-301, LSTA12, FCR-001, and others are expected to have a significant impact on the Hematopoietic Stem Cell Transplantation market in the coming years. In May 2022, In order to begin a Phase 2b/3 research using mocravimod in acute myeloid leukaemia (AML) patients undergoing allogeneic hematopoietic stem cell transplant (HSCT), Priothera received approval from the US Food and Drug Administration (FDA). In December 2021, the United States Food and Drug Administration approved the treatment to prevent acute graft-versus-host disease (GVHD) in patients of 2 years of age or older receiving a hematopoietic stem cell transplant from a matched or single-HLA-mismatched unrelated donor.
Hematopoietic Stem Cell Transplantation Overview Hematopoietic stem cell transplant (HPSCT), also known as a bone marrow transplant, involves giving patients who have malfunctioning or depleted bone marrow viable hematopoietic stem cells. Clinical HPSCT comes in a variety of forms, and the transplanted cells might come from many sources.
Get a Free Sample PDF Report to know more about Hematopoietic Stem Cell Transplantation Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/hematopoietic-stem-cell-transplantation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Hematopoietic Stem Cell Transplantation Drugs Under Different Phases of Clinical Development Include: OTL-204: Orchard Therapeutics OTL-105: Orchard Therapeutics LSTA201: Lisata Therapeutics Temferon: Genenta science EDIT-301: Editas Medicine LSTA12: Lisata Therapeutics FCR-001: Talaris Therapeutics, Inc.
Hematopoietic Stem Cell Transplantation Route of Administration Hematopoietic Stem Cell Transplantation pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as Intravenous
Hematopoietic Stem Cell Transplantation Molecule Type Hematopoietic Stem Cell Transplantation Products have been categorized under various Molecule types, such as Peptide Protein Propylene glycols Cell Therapy
Hematopoietic Stem Cell Transplantation Pipeline Therapeutics Assessment Hematopoietic Stem Cell Transplantation Assessment by Product Type Hematopoietic Stem Cell Transplantation By Stage and Product Type Hematopoietic Stem Cell Transplantation Assessment by Route of Administration Hematopoietic Stem Cell Transplantation By Stage and Route of Administration Hematopoietic Stem Cell Transplantation Assessment by Molecule Type Hematopoietic Stem Cell Transplantation by Stage and Molecule Type
DelveInsight's Hematopoietic Stem Cell Transplantation Report covers around 20+ products under different phases of clinical development like Late-stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration
Further Hematopoietic Stem Cell Transplantation product details are provided in the report. Download the Hematopoietic Stem Cell Transplantation pipeline report to learn more about the emerging Hematopoietic Stem Cell Transplantation therapies https://www.delveinsight.com/sample-request/hematopoietic-stem-cell-transplantation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Hematopoietic Stem Cell Transplantation Therapeutics Market include: Key companies developing therapies for Hematopoietic Stem Cell Transplantation are - STEMCELL Technologies, Inc., Pluristem Therapeutics, Inc., Merck KGaA, ScienCell Research Laboratories, Inc., Lonza Group, and others.
Hematopoietic Stem Cell Transplantation Pipeline Analysis: The Hematopoietic Stem Cell Transplantation pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Hematopoietic Stem Cell Transplantation with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hematopoietic Stem Cell Transplantation Treatment. Hematopoietic Stem Cell Transplantation key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Hematopoietic Stem Cell Transplantation Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hematopoietic Stem Cell Transplantation market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Hematopoietic Stem Cell Transplantation drugs and therapies https://www.delveinsight.com/sample-request/hematopoietic-stem-cell-transplantation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Hematopoietic Stem Cell Transplantation Pipeline Market Drivers The Rise in the prevalence of Malignant Diseases, increasing Research and Developmental Activities are some of the important factors that are fueling the Hematopoietic Stem Cell Transplantation Market.
Hematopoietic Stem Cell Transplantation Pipeline Market Barriers However, lack of Knowledge and Risks Associated, post-HSCT Complications and other factors are creating obstacles in the Hematopoietic Stem Cell Transplantation Market growth.
Scope of Hematopoietic Stem Cell Transplantation Pipeline Drug Insight Coverage: Global Key Hematopoietic Stem Cell Transplantation Companies: Orchard Therapeutics, Lisata Therapeutics, Genenta science, Editas Medicine, Talaris Therapeutics, Inc., and others Key Hematopoietic Stem Cell Transplantation Therapies: OTL-204, OTL-105, LSTA201, Temferon, EDIT-301, LSTA12, FCR-001, and others Hematopoietic Stem Cell Transplantation Therapeutic Assessment: Hematopoietic Stem Cell Transplantation current marketed and Hematopoietic Stem Cell Transplantation emerging therapies Hematopoietic Stem Cell Transplantation Market Dynamics: Hematopoietic Stem Cell Transplantation market drivers and Hematopoietic Stem Cell Transplantation market barriers
Request for Sample PDF Report for Hematopoietic Stem Cell Transplantation Pipeline Assessment and clinical trials https://www.delveinsight.com/sample-request/hematopoietic-stem-cell-transplantation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents 1. Hematopoietic Stem Cell Transplantation Report Introduction 2. Hematopoietic Stem Cell Transplantation Executive Summary 3. Hematopoietic Stem Cell Transplantation Overview 4. Hematopoietic Stem Cell Transplantation- Analytical Perspective In-depth Commercial Assessment 5. Hematopoietic Stem Cell Transplantation Pipeline Therapeutics 6. Hematopoietic Stem Cell Transplantation Late Stage Products (Phase II/III) 7. Hematopoietic Stem Cell Transplantation Mid Stage Products (Phase II) 8. Hematopoietic Stem Cell Transplantation Early Stage Products (Phase I) 9. Hematopoietic Stem Cell Transplantation Preclinical Stage Products 10. Hematopoietic Stem Cell Transplantation Therapeutics Assessment 11. Hematopoietic Stem Cell Transplantation Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Hematopoietic Stem Cell Transplantation Key Companies 14. Hematopoietic Stem Cell Transplantation Key Products 15. Hematopoietic Stem Cell Transplantation Unmet Needs 16 . Hematopoietic Stem Cell Transplantation Market Drivers and Barriers 17. Hematopoietic Stem Cell Transplantation Future Perspectives and Conclusion 18. Hematopoietic Stem Cell Transplantation Analyst Views 19. Appendix 20. About DelveInsight
Related Reports:
Hematopoietic Stem Cell Transplantation Market https://www.delveinsight.com/report-store/hematopoietic-stem-cell-transplantation-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr DelveInsight's 'Hematopoietic Stem Cell Transplantation Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Hematopoietic Stem Cell Transplantation Epidemiology https://www.delveinsight.com/report-store/hematopoietic-stem-cell-transplantation-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr DelveInsight's 'Hematopoietic Stem Cell Transplantation Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
Aneurysmal Subarachnoid Hemorrhage Market https://www.delveinsight.com/report-store/aneurysmal-subarachnoid-hemorrhage-sah-market DelveInsight's "Aneurysmal Subarachnoid Hemorrhage (SAH) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Aneurysmal Subarachnoid Hemorrhage (SAH), historical and forecasted epidemiology as well as the Aneurysmal Subarachnoid Hemorrhage (SAH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Angelman Syndrome Market https://www.delveinsight.com/report-store/angelman-syndrome-market-forecast DelveInsight's "Angelman Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Angelman Syndrome, historical and forecasted epidemiology as well as the Angelman Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Autoimmune Pulmonary Alveolar Proteinosis Market https://www.delveinsight.com/report-store/autoimmune-pulmonary-alveolar-proteinosis-apap-market DelveInsight's "Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of Autoimmune pulmonary alveolar proteinosis, historical and forecasted epidemiology as well as Autoimmune pulmonary alveolar proteinosis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Cardiovascular Calcification Market https://www.delveinsight.com/report-store/cardiovascular-calcification-market DelveInsight's "Cardiovascular Calcification Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Cardiovascular Calcification, historical and forecasted epidemiology as well as the Cardiovascular Calcification market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Charcot Marie Tooth Disease Market https://www.delveinsight.com/report-store/charcot-marie-tooth-disease-market DelveInsight's 'Charcot-Marie-Tooth Disease Market Insights, Epidemiology, and Market Forecast 2032' report deliver an in-depth understanding of the Charcot-Marie-Tooth Disease, historical and forecasted epidemiology as well as the Charcot-Marie-Tooth Disease market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Contact Us: Gaurav Bora gbora@delveinsight.com +14699457679 Healthcare Consulting https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.